Objective: The authors examined the safety and efficacy of antidepressants added to
antipsychotic drugs in the treatment of schizophrenia. Method: Multiple databases and …

Negative symptoms in schizophrenia may be classified as primary or secondary. Primary
negative symptoms are thought to be intrinsic to schizophrenia, while secondary negative …

The introduction of second-generation antipsychotics and cognitive therapies for
schizophrenia over the past two decades generated considerable optimism about …

These guidelines from the British Association for Psychopharmacology address the scope
and targets of pharmacological treatment for schizophrenia. A consensus meeting, involving …

Suicide is a major cause of death among patients with schizophrenia. Research indicates
that at least 5–13% of schizophrenic patients die by suicide, and it is likely that the higher …

Major depression is a debilitating and recurrent disorder with a substantial lifetime risk and a
high social cost. Depressed patients generally display co-morbid symptoms, and depression …

For every disorder, there is a set of established findings and accepted constructs upon which
further understanding is built. The concept of schizophrenia as a disease entity has been …

These updated guidelines from the British Association for Psychopharmacology replace the
original version published in 2011. They address the scope and targets of pharmacological …

With new data about different aspects of schizophrenia being continually generated, it
becomes necessary to periodically revisit exactly what we know. Along with a need to review …

Comorbid major depressive disorder (MDD) in schizophrenia (SZ; SZ-MDD) has been
identified as a major prognostic factor. However, the prevalence and associated factors of …